- ISIN
- US92790C1045
- CUSIP
- 92790C104
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 18, 2014
Highlights
- Market Cap
- $1.70B
- Enterprise Value
- $1.53B
- EPS (TTM)
- -$4.02
- Total Revenue (TTM)
- $70.92M
- Gross Profit (TTM)
- $70.46M
- EBITDA (TTM)
- -$364.29M
- Year Range
- $13.18 - $34.29
- Target Price
- $42.00
- ROA (TTM)
- -45.70%
- ROE (TTM)
- -56.70%
- Avg. Volume (1M)
- 2M
- Avg. Volume Value (1M)
- $33.98M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
VRDN Performance Chart
Viridian Therapeutics, Inc. (VRDN) is down 39.2% since the beginning of the year. At $19 per share, VRDN is trading 44.8% below its 52-week high of $34. Investors who bought $1,000 worth of VRDN shares 5 years ago would now be looking at an investment worth $1,218.
Loading charts...
Compare this symbol against anything
Returns By Period
Viridian Therapeutics, Inc. (VRDN) has returned -39.20% so far this year and 8.67% over the past 12 months. Over the last ten years, VRDN has returned -16.16% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
Viridian Therapeutics, Inc.
- 1D
- -4.92%
- 1M
- -2.47%
- 6M
- -42.67%
- YTD
- -39.20%
- 1Y
- 8.67%
- 3Y*
- 0.48%
- 5Y*
- 4.03%
- 10Y*
- -16.16%
- ALL TIME*
- -32.15%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
VRDN Monthly Returns History
Based on dividend-adjusted daily data since Jun 18, 2014, VRDN's average daily return is +0.08%, while the average monthly return is +0.38%. At this rate, an investment would double in approximately 15.2 years.
Historically, 41% of months were positive and 59% were negative. The best month was Jan 2020 with a return of +264.6%, while the worst month was Feb 2020 at -57.5%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 8 months.
On a daily basis, VRDN closed higher 45% of trading days. The best single day was Jan 10, 2017 with a return of +264.9%, while the worst single day was Feb 7, 2020 at -37.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 6.04% | -10.97% | -33.42% | -31.08% | 30.71% | 4.26% | 2.99% | -39.20% | |||||
| 2025 | 1.10% | -19.87% | -13.20% | 0.52% | 2.73% | 0.43% | 25.32% | 4.91% | 17.41% | 9.50% | 35.25% | -2.63% | 62.34% |
| 2024 | -11.62% | -2.81% | -6.41% | -24.27% | -9.88% | 8.87% | 29.52% | -12.88% | 54.97% | -5.19% | -0.09% | -11.04% | -11.98% |
| 2023 | 25.03% | -10.30% | -22.34% | 10.18% | -14.98% | -0.17% | -21.14% | -3.14% | -15.58% | -18.51% | 33.92% | 30.11% | -25.44% |
| 2022 | 1.67% | -10.10% | 2.32% | -25.58% | -11.34% | -5.16% | 14.43% | 67.75% | -7.65% | -2.97% | 26.98% | 15.59% | 47.75% |
| 2021 | 8.33% | -7.74% | 1.64% | 9.22% | -1.32% | 1.55% | -15.12% | -13.82% | 22.94% | 10.03% | 6.30% | 2.75% | 20.18% |
Benchmark Metrics
Viridian Therapeutics, Inc. has an annualized alpha of 10.73%, beta of 0.79, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since June 18, 2014.
- This stock participated in 178.99% of S&P 500 Index downside but only -15.91% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 10.73%
- Beta
- 0.79
- R²
- 0.01
- Upside Capture
- -15.91%
- Downside Capture
- 178.99%
Return for Risk
Risk / Return Rank
VRDN ranks 50 for risk / return — above 50% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Viridian Therapeutics, Inc. (VRDN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VRDN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.30 | ||
| Sortino ratioReturn per unit of downside risk | -1.30 | ||
| Omega ratioGain probability vs. loss probability | 1.11 | 1.25 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 0.13 | 2.00 | -1.87 |
| Martin ratioReturn relative to average drawdown | 0.27 | 8.49 | -8.22 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Viridian Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Viridian Therapeutics, Inc. was 99.74%, occurring on Mar 19, 2020. The portfolio has not yet recovered.
The current Viridian Therapeutics, Inc. drawdown is 99.09%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.74%Mar 2020 | 5y 9mo | — | 12y 1moJun 2014 - now | COVID crash2020 |
Drawdown Indicators
| VRDN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.74% | -56.78% | -42.96% |
Max Drawdown (1Y)Largest decline over 1 year | -60.63% | -9.10% | -51.53% |
Max Drawdown (3Y)Largest decline over 3 years | -60.63% | -18.90% | -41.73% |
Max Drawdown (5Y)Largest decline over 5 years | -70.69% | -25.43% | -45.26% |
Max Drawdown (10Y)Largest decline over 10 years | -97.92% | -33.92% | -64.00% |
Current DrawdownCurrent decline from peak | -99.09% | -1.58% | -97.51% |
Average DrawdownAverage peak-to-trough decline | -94.28% | -10.70% | -83.58% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 29.93% | 2.14% | +27.79% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Viridian Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Viridian Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for VRDN relative to other companies in the Biotechnology industry. Currently, VRDN has a P/S ratio of 23.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for VRDN in comparison with other companies in the Biotechnology industry. Currently, VRDN has a P/B value of 3.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with VRDN
Add Viridian Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with VRDN